Trial Profile
A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With DLBCL
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 27 Nov 2023 Status changed from active, no longer recruiting to completed.
- 04 May 2022 Planned End Date changed from 11 Feb 2024 to 25 Nov 2023.
- 18 Feb 2021 Planned End Date changed from 21 Aug 2024 to 11 Feb 2024.